FY2020 Earnings Estimate for Ultragenyx Pharmaceutical Inc. (RARE) Issued By Leerink Swann

FY2020 Earnings Estimate for Ultragenyx Pharmaceutical Inc. (RARE) Issued By Leerink Swann

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) – Equities research analysts at Leerink Swann dropped their FY2020 EPS estimates for shares of Ultragenyx Pharmaceutical in a note issued to investors on Friday. Leerink Swann analyst J. Schwartz now forecasts that the brokerage will post earnings of $0.17 per share for the year, down from their previous estimate of $0.21. Leerink Swann currently has a “Outperform” rating and a $94.00 target price on the stock.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last issued its quarterly earnings data on Monday, November 7th. The biopharmaceutical company reported ($1.64) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.53) by $0.11. During the same quarter in the prior year, the company earned ($1.03) earnings per share.

A number of other equities analysts also recently commented on RARE. Piper Jaffray Cos. reiterated an “overweight” rating and set a $70.00 price objective on shares of Ultragenyx Pharmaceutical in a research report on Sunday, July 17th. Jefferies Group reiterated a “buy” rating on shares of Ultragenyx Pharmaceutical in a research report on Sunday, July 17th. Robert W. Baird reiterated an “outperform” rating and set a $85.00 price objective on shares of Ultragenyx Pharmaceutical in a research report on Monday, July 18th. Wedbush reiterated an “outperform” rating and set a $92.00 price objective on shares of Ultragenyx Pharmaceutical in a research report on Tuesday, August 9th. Finally, Credit Suisse Group AG reiterated a “buy” rating and set a $101.00 price objective on shares of Ultragenyx Pharmaceutical in a research report on Tuesday, August 9th. One analyst has rated the stock with a sell rating, two have issued a hold rating, fourteen have issued a buy rating and one has given a strong buy rating to the company. Ultragenyx Pharmaceutical currently has a consensus rating of “Buy” and an average price target of $94.70.

Shares of Ultragenyx Pharmaceutical (NASDAQ:RARE) opened at 82.06 on Monday. The company’s 50-day moving average price is $66.41 and its 200-day moving average price is $63.72. Ultragenyx Pharmaceutical has a 12 month low of $46.52 and a 12 month high of $117.12. The company’s market cap is $3.35 billion.

In related news, CFO Shalini Sharp sold 24,000 shares of the business’s stock in a transaction on Wednesday, November 9th. The stock was sold at an average price of $71.20, for a total value of $1,708,800.00. Following the sale, the chief financial officer now owns 69,387 shares in the company, valued at approximately $4,940,354.40. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CEO Emil D. Kakkis sold 20,000 shares of the business’s stock in a transaction on Friday, October 14th. The shares were sold at an average price of $63.02, for a total value of $1,260,400.00. Following the completion of the sale, the chief executive officer now owns 480,632 shares in the company, valued at approximately $30,289,428.64. The disclosure for this sale can be found here. 10.10% of the stock is owned by corporate insiders.

Several large investors have recently bought and sold shares of the stock. State Street Corp increased its stake in Ultragenyx Pharmaceutical by 30.6% in the first quarter. State Street Corp now owns 1,284,324 shares of the biopharmaceutical company’s stock valued at $81,315,000 after buying an additional 300,901 shares in the last quarter. Geode Capital Management LLC increased its stake in Ultragenyx Pharmaceutical by 4.0% in the first quarter. Geode Capital Management LLC now owns 257,713 shares of the biopharmaceutical company’s stock valued at $16,315,000 after buying an additional 9,987 shares in the last quarter. Adage Capital Partners GP L.L.C. increased its stake in Ultragenyx Pharmaceutical by 45.0% in the first quarter. Adage Capital Partners GP L.L.C. now owns 483,500 shares of the biopharmaceutical company’s stock valued at $30,610,000 after buying an additional 150,000 shares in the last quarter. Springbok Capital Management LLC purchased a new stake in Ultragenyx Pharmaceutical during the first quarter valued at about $189,000. Finally, Bellevue Group AG purchased a new stake in Ultragenyx Pharmaceutical during the first quarter valued at about $633,000. Hedge funds and other institutional investors own 93.01% of the company’s stock.

Ultragenyx Pharmaceutical Company Profile

Related posts

Leave a Comment